Drugs Health Pharma

EMA expands inquiry into suicidal thoughts linked to GLP-1 weight loss drugs

HQ Team December 2, 2023: The European Medicines Agency (EMA) is intensifying its investigation into the potential link between certain GLP-1 receptor agonist.

Read More
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More
Drugs Health Pharma

FDA probes failure of syringes made in China for possible breakages

HQ Team December 1, 2023: The US Food and Drug Administration (USFDA) is assessing the potential for failures in plastic syringes manufactured in.

Read More
Climate Drugs Pharma

WHO global malaria strategy ‘off track by a wide margin’

HQ Team November 30, 2023: The Covid-19 pandemic significantly disrupted malaria services, leading to a surge in both incidence and mortality rates, exacerbating.

Read More
Drugs Health Pharma

AbbVie to buy Immunogen for $10.1b to expand solid tumour market

HQ Team November 30, 2023: AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to.

Read More
Drugs Health Medical

Exercise, a promising approach to tackle postpartum depression

HQ Team November 30, 2023: Postpartum depression is a common psychological affliction following childbirth and affects 17.22% of the world population. Postpartum depression.

Read More
Drugs Health Pharma

Opinion: Feast for G20 leaders, benefits of millets exceed rice, wheat

By Dr. K. Leelamoni November 30, 2023: The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023.

Read More
Drugs Health Pharma

First new strain of swine flu detected in UK, probe on to track virus origins

HQ Team November 29, 2023: The first human case of a new swine flu variant in the UK has been detected by the.

Read More
Drugs Health Pharma

Omicron mutant BA.2.86 reclassified as ‘variant of interest’ by WHO 

HQ Team November 29, 2023: The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global.

Read More
Drugs Health Pharma

FDA probing T cell cancer therapies of Gilead Sciences, Novartis, J & J

HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.

Read More
X